Diverse cells make up the endothelium
Cells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Microbiome defines gut conditions
Differences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report.
Cellestia Biotech AG attracts Series A financing
Cancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing.
Staten Biotechnology in $430m deal with Novo Nordisk
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Kurma Partners announce closing of Biofund III
Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise €150m.
MEPs back €120bn budget for Horizon Europe
The European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
New cheap CRS-blockers at the horizon
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.
Are novel antibiotics worth investing in?
In autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the screen, discussion about which pull mechanism should be started first is in full swing. Meanwhile, small and medium-sized companies combine forces aiming to propel preclinical and early clinical R&D.
Oxford BioTherapeutics in $450 deal with Wuxi Biologics
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics’ WuXiBody platform.
Diabetes doubles risk for heart failure
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.